Skip to main content
Premium Trial:

Request an Annual Quote

AI Startup Envisagenics Closes $2.4M Seed Round

CHICAGO (GenomeWeb) – Envisagenics, a startup focused on aiding drug discovery by applying artificial intelligence to gene sequences, has closed a $2.4 million seed round of venture capital.

The lead investors are mostly women, including Daniella Kranjac, managing director of Dynamk Capital; Shana Fisher, founder of Third Kind Venture Capital; and Gillian Sandler, of New York biotech investment company Cosine, the firm said. Envisagenics also received funding from Peter Thiel's Breakout Labs and from the New York State Innovation Venture Capital Fund.

New York-based Envisagenics, which was spun out of Cold Spring Harbor Laboratory in 2014, launched its SpliceCore technology platform in October at Breakout Labs' pitch competition, Unboxing. SpliceCore helps drug companies develop new therapies that correct RNA splicing errors, the startup said.

"Discovering RNA splicing errors and learning how to fix them at the same time is a fantastic problem to solve with AI,” Envisagenics Cofounder and Chief Technology Officer Martin Akerman noted in a statement.

Envisagenics developed the prototype for SpliceCore with the help of a $225,000 grant from the National Institutes of Health in 2015.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.